Great C19 vax data💉

Novavax PREVENT-19 trial:
30k participants 2:1 randomized, placebo-controlled

VE symptoms+PCR = 90.4% [82.9,94.6]
VE moderate/severe disease = 100% [87.0,100]

no statically significant difference w/ VOC or high risk population (>65 or severe comorbidities)

— Devan Sinha (@DevanSinha) June 14, 2021